Context Therapeutics (CNTX) vs Evaxion A/S (EVAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Evaxion A/S (EVAX) has outperformed Context Therapeutics (CNTX) over the past year, losing 51.5% versus a loss of 73.8%. Context Therapeutics is the larger company by market cap ($27.6 million vs $27.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTX | EVAX |
|---|---|---|
| Share price | $0.3001 | $3.04 |
| Market cap | $27.57M | $27.38M |
| 1-day change | +0.37% | -0.49% |
| YTD return | -79.66% | -36.06% |
| 1-year return | -73.77% | -51.51% |
| 5-year return | — | -99.23% |
| EPS (TTM) | $-0.48 | $-1.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.62 | $12.15 |
| 52-week low | $0.295 | $2.77 |
| Distance from 52-week high | -91.71% | -75.02% |
| Analyst consensus | none | none |
| Avg. price target upside | +1242.89% | +270.68% |
| Average volume | 1.66M | 200.14K |
| Shares outstanding | 91.88M | 9.02M |
| Employees | 15 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EVAX has outperformed CNTX by 22.3 percentage points over the past year.
About Context Therapeutics
CNTX stock →Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Evaxion A/S
EVAX stock →Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
CNTX vs EVAX FAQ
Which is bigger, Context Therapeutics or Evaxion A/S?
Context Therapeutics (CNTX) is larger, with a market capitalization of $27.57M compared with $27.38M for Evaxion A/S (EVAX).
Which stock has performed better over the past year, CNTX or EVAX?
EVAX returned -51.51% over the past 12 months, compared with -73.77% for CNTX (price return, excluding dividends). Past performance does not predict future results.
Are Context Therapeutics and Evaxion A/S in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Context Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Evaxion A/S.